Chengdu Kanghua Biological Products Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chengdu Kanghua Biological Products Co., Ltd. (hereinafter referred to as "Kanghua Biological", stock code: 300841) is a biopharmaceutical enterprise engaged in the research and development, production, and sales of biological products, committed to innovative biopharmaceutical products and services to make human life better. In 2004, Kanghua Biotechnology was established in the National Economic and Technological Development Zone of Chengdu. In September 2018, the company expanded its scale and signed a contract with the Wenjiang District Government of Chengdu to select Area A of the International Medical City as the research and development and production base for new vaccines. Kanghua Biotechnology is equipped with an animal testing center and a high-tech GMP production workshop for bacterial and viral vaccines. Its existing products include "ACYW135 meningococcal polysaccharide vaccine" (trade name: Maixin) and "freeze-dried human rabies vaccine (human diploid cells)" (trade name: HDCV). Kanghua Biotechnology adheres to innovation as its research and development direction, adopting a research and development model that combines independent research and development with joint research and development, and has established an efficient research and development innovation management model. Kanghua Biotechnology has established multiple vaccine research and development platforms based on research and development centers and postdoctoral research workstations, and has undertaken and participated in projects such as the National 863 Plan and the transformation of provincial scientific and technological achievements. While vigorously building and strengthening independent research and development capabilities, the company actively promotes external cooperation and has established cooperative relationships with numerous universities, research institutes, and outstanding enterprises with outstanding research and development capabilities. Since its establishment, Kanghua Biotechnology has been awarded honorary titles such as "Postdoctoral Innovation Practice Base", "Sichuan Province Constructive Innovation Enterprise Cultivation Enterprise", and "Sichuan Province Excellent Integrity Demonstration Unit" by the Department of Personnel and the Department of Science and Technology. |
| Headquarter | Chengdu |
| Establish Date | 4/2/2004 |
| Listed Code | 300841.SZ |
| Listed Date | 6/16/2020 |
| Chairman | Wang Zhentao. |
| CEO | Wu Hongbo. |
| Website | www.kangh.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
